With the almost explosive evolution of new data on the nature of tumor biology, the mandate for cooperative groups in the forseeable future becomes increasingly more challenging and complex. Information on tumor biology must be incorporated into the development of feasible group-will and intra(sub) group phase II/III studies. As a result, protocols designed for specific subgroups in acute lymphoblastic leukemia must address T-cell and B-cell subtypes and continue to delve into the nature of pre-B and pre-T subtypes. In AML, efforts must be made to identify risk factors whilst utilizing randomized trials of best available """"""""standard"""""""" therapy. In this regard, efforts must be made to evaluate new combinations of proven therapy utilizing new knowledge of (1) drug-drug interaction, (2) efficacy of high or mega-dose therapy, and (3) the role of """"""""cleansing"""""""" techniques. Examples of (1) include methotrexate-asparaginase, (2) high dose cytosine arabinoside, and (3) antibody purging. Bone marrow transplantation as a major therapeutic arm deserves intensive evaluation. The University of Florida has developed a most favorable preparative regimen for second remission ALL, as part of an 8 institution POG study which, which it will now apply to first remission high risk ALL. A proposal for marrow transplantation in second remission AML is now available for group use, and bone marrow transplantation is underway in high risk neuroblastoma, and is being piloted locally in Hodgkin's disease, Ewing's sarcoma and non-Hodgkin's lymphoma. Bone marrow cleansing with antibody coated magnetized microspheres directed against neuroblastoma, cALLa(+), ALL and T-cell ALL are underway locally. The University of Florida Bone Marrow Transplantation Unit is also a component of a multi-institution CML transplantation study. In addition to active participation in whole group efforts, ongoing programs in pharmacology and pharmacokinetics will continue in order to design regimens which will address the propitious use of chemotherapeutic agents. Finally, this division has expanded its program to include University Hospital of Jacksonville, has submitted additional institutions for cancer control and has broadened its range of studies in genetics and long term effects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA029281-09
Application #
3557052
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1981-01-01
Project End
1990-12-31
Budget Start
1989-01-01
Budget End
1989-12-31
Support Year
9
Fiscal Year
1989
Total Cost
Indirect Cost
Name
University of Florida
Department
Type
Schools of Medicine
DUNS #
073130411
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Turner, C; Gross, S (1994) Treatment of recurrent suprahyoid cervicofacial lymphangioma with intravenous cyclophosphamide. Am J Pediatr Hematol Oncol 16:325-8
Mendenhall, N P; Cantor, A B; Williams, J L et al. (1993) With modern imaging techniques, is staging laparotomy necessary in pediatric Hodgkin's disease? A Pediatric Oncology Group study. J Clin Oncol 11:2218-25
Crist, W; Shuster, J; Look, T et al. (1992) Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group. Leukemia 6 Suppl 2:162-6
Laver, J H; Xu, F; Barredo, J C et al. (1992) Effects of radiation and 4-hydroperoxycyclophosphamide on production of G- and GM-CSF by stromal cells. Bone Marrow Transplant 10:529-33
Vats, T; Buchanan, G; Mehta, P et al. (1992) A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse. A Pediatric Oncology Group study. Invest New Drugs 10:231-4
Weiner, M A; Leventhal, B G; Marcus, R et al. (1991) Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol 9:1591-8
Steuber, C P; Civin, C; Krischer, J et al. (1991) A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study. J Clin Oncol 9:247-58
Graham-Pole, J; Gee, A; Emerson, S et al. (1991) Myeloablative chemoradiotherapy and autologous bone marrow infusions for treatment of neuroblastoma: factors influencing engraftment. Blood 78:1607-14
Bazer, F W; Worthington-White, D; Fliss, M F et al. (1991) Uteroferrin: a progesterone-induced hematopoietic growth factor of uterine origin. Exp Hematol 19:910-5
Carroll, A; Civin, C; Schneider, N et al. (1991) The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study. Blood 78:748-52

Showing the most recent 10 out of 23 publications